Sergio Giralt

62.4k total citations · 6 hit papers
856 papers, 30.2k citations indexed

About

Sergio Giralt is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Sergio Giralt has authored 856 papers receiving a total of 30.2k indexed citations (citations by other indexed papers that have themselves been cited), including 649 papers in Hematology, 283 papers in Oncology and 151 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Sergio Giralt's work include Hematopoietic Stem Cell Transplantation (378 papers), Multiple Myeloma Research and Treatments (216 papers) and Acute Myeloid Leukemia Research (207 papers). Sergio Giralt is often cited by papers focused on Hematopoietic Stem Cell Transplantation (378 papers), Multiple Myeloma Research and Treatments (216 papers) and Acute Myeloid Leukemia Research (207 papers). Sergio Giralt collaborates with scholars based in United States, United Kingdom and Spain. Sergio Giralt's co-authors include Richard E. Champlin, Issa F. Khouri, Börje S. Andersson, Marcos de Lima, Paolo Anderlini, Donna Przepiorka, James Gajewski, Koen van Besien, Chitra Hosing and Daniel R. Couriel and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Sergio Giralt

809 papers receiving 29.6k citations

Hit Papers

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION ... 1997 2026 2006 2016 1998 1997 1997 1998 2014 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
    1998 1.2k citations Sergio Giralt et al. profile →
  2. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
    1997 993 citations Sergio Giralt, Richard E. Champlin et al. profile →
  3. Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
    1997 909 citations Sergio Giralt, Gabriela Rondón et al. Blood profile →
  4. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
    1998 738 citations Issa F. Khouri, Paolo Anderlini et al. profile →
  5. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
    2014 614 citations Miguel‐Angel Perales, Parastoo B. Dahi et al. Blood profile →
  6. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
    2017 400 citations Mehdi Hamadani, Sergio Giralt et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sergio Giralt United States 86 21.4k 10.0k 7.0k 5.6k 5.0k 856 30.2k
Mohamad Mohty France 82 18.6k 0.9× 7.6k 0.8× 6.4k 0.9× 4.3k 0.8× 3.4k 0.7× 928 26.0k
Dietger Niederwieser Germany 73 18.3k 0.9× 5.4k 0.5× 6.1k 0.9× 4.4k 0.8× 7.5k 1.5× 535 26.8k
Gèrard Socié France 91 18.7k 0.9× 7.4k 0.7× 9.2k 1.3× 3.4k 0.6× 4.8k 0.9× 701 30.2k
Hillard M. Lazarus United States 76 13.4k 0.6× 7.0k 0.7× 3.9k 0.6× 4.6k 0.8× 5.9k 1.2× 545 25.8k
H. Joachim Deeg United States 94 23.2k 1.1× 7.1k 0.7× 6.8k 1.0× 3.7k 0.7× 6.4k 1.3× 669 31.0k
Daniel J. Weisdorf United States 96 24.2k 1.1× 11.4k 1.1× 13.3k 1.9× 5.1k 0.9× 5.1k 1.0× 732 38.4k
Richard E. Champlin United States 113 27.2k 1.3× 14.9k 1.5× 12.6k 1.8× 6.7k 1.2× 8.4k 1.7× 1.1k 45.3k
Robert J. Soiffer United States 89 15.0k 0.7× 7.1k 0.7× 10.6k 1.5× 2.7k 0.5× 3.7k 0.7× 506 25.4k
Frederick R. Appelbaum United States 105 30.9k 1.4× 10.1k 1.0× 7.0k 1.0× 9.8k 1.8× 8.9k 1.8× 595 42.6k
Gerhard Ehninger Germany 78 13.6k 0.6× 6.5k 0.7× 4.3k 0.6× 6.1k 1.1× 5.2k 1.0× 678 25.0k

Countries citing papers authored by Sergio Giralt

Since Specialization
Citations

This map shows the geographic impact of Sergio Giralt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio Giralt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio Giralt more than expected).

Fields of papers citing papers by Sergio Giralt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergio Giralt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio Giralt. The network helps show where Sergio Giralt may publish in the future.

Co-authorship network of co-authors of Sergio Giralt

This figure shows the co-authorship network connecting the top 25 collaborators of Sergio Giralt. A scholar is included among the top collaborators of Sergio Giralt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergio Giralt. Sergio Giralt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jolles, Stephen, Sergio Giralt, Tessa Kerre, et al.. (2023). Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review. Frontiers in Oncology. 13. 1098326–1098326. 10 indexed citations
2.
Devlin, Sean M., Beatriz Wills, Amethyst Saldia, et al.. (2023). Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy. Blood. 142(Supplement 1). 3510–3510. 1 indexed citations
3.
Derkach, Andriy, Billel Gasmi, Theodora Anagnostou, et al.. (2023). T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis. Blood. 142(Supplement 1). 3326–3326. 1 indexed citations
4.
Nath, Karthik, Samantha Brown, Sean M. Devlin, et al.. (2023). Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 30(1). 81–92.
5.
Lin, Andrew, Samantha Brown, Yeon Joo Lee, et al.. (2023). Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Advances. 7(23). 7153–7160. 6 indexed citations
6.
Shah, Gunjan L., David J. Chung, Roni Tamari, et al.. (2022). Humoral Response to COVID-19 Vaccination Given Pre-Cellular Therapy Wanes in Patients after Cellular Therapy: An Argument for Full Reimmunization. Transplantation and Cellular Therapy. 28(3). S373–S374. 1 indexed citations
7.
Lin, Andrew, Samantha Brown, Molly Maloy, et al.. (2022). Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation. Leukemia & lymphoma. 63(7). 1686–1693. 2 indexed citations
8.
Scordo, Michael, Leah Gilbert, Jessica Flynn, et al.. (2022). Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation. Blood Advances. 7(8). 1536–1544. 4 indexed citations
9.
Landau, Heather, Elizabeth Rodríguez, Allison J. Applebaum, et al.. (2022). Pilot Trial of Homebound Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(12). 832.e1–832.e7. 5 indexed citations
10.
Hultcrantz, Malin, Even H. Rustad, Venkata Yellapantula, et al.. (2022). Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research. 28(10). 2160–2166. 1 indexed citations
11.
Shah, Nishi, Ana Alarcón Tomás, Josel D. Ruiz, et al.. (2021). High Rates of Residual Vaccine Titers at 1-Year Post CD19 Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 27(3). S355–S355. 3 indexed citations
12.
Khaled, Samer K., Jaap Jan Boelens, Mitchell S. Cairo, et al.. (2021). Narsoplimab (OMS721), a Masp-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA). Transplantation and Cellular Therapy. 27(3). S24–S26. 2 indexed citations
13.
14.
Lahoud, Oscar, Sean M. Devlin, Molly Maloy, et al.. (2021). Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter’s transformation. Blood Advances. 5(14). 2879–2889. 18 indexed citations
15.
Oran, Betül, Marcos de Lima, Guillermo Garcia‐Manero, et al.. (2020). A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Advances. 4(21). 5580–5588. 132 indexed citations
16.
Lin, Andrew, Molly Maloy, Yiqi Su, et al.. (2019). Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experience. Transplant Infectious Disease. 21(6). e13187–e13187. 65 indexed citations
17.
18.
Lendvai, Nikoletta, Patrick Hilden, Sean M. Devlin, et al.. (2014). A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 124(6). 899–906. 65 indexed citations
19.
Giralt, Sergio. (2012). Stem cell transplantation for multiple myeloma: current and future status. Hematology. 17(sup1). s117–s120. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohamad Mohty Breakdown of academic impact, for papers by Dietger Niederwieser Breakdown of academic impact, for papers by Gèrard Socié Breakdown of academic impact, for papers by Hillard M. Lazarus Breakdown of academic impact, for papers by H. Joachim Deeg Breakdown of academic impact, for papers by Daniel J. Weisdorf Breakdown of academic impact, for papers by Richard E. Champlin Breakdown of academic impact, for papers by Robert J. Soiffer Breakdown of academic impact, for papers by Frederick R. Appelbaum Breakdown of academic impact, for papers by Gerhard Ehninger
Rankless by CCL
2026